# Wave Life Sciences to Present at Upcoming Investor Conferences - Wave Life Sciences
Canonical URL: https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-wave-life-science-1abd2202
Ticker: WVE
Company: Wave Life Sciences
Source: Wave Life Sciences
Published: 2026-07-09 15:18 EST
Original Source URL: https://ir.wavelifesciences.com/news-releases
## Summary

The Investor Relations website contains information about Wave Life Sciences's business for stockholders, potential investors, and financial analysts.

## Article Body
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in June.

2026 Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET

Goldman Sachs 47 th Annual Global Healthcare Conference Date: Monday, June 8, 2026 Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m. ET

Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events . Replays of these presentations will be archived and available on the site for a limited time following the event.

About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn .

Contact: Kate Rausch VP, Corporate Affairs and Investor Relations +1 617-949-4827

Investors: James Salierno Director, Investor Relations +1 617-949-4043 [email protected]

Media : Katie Sullivan Senior Director, Corporate Communications +1 617-949-2936 [email protected]
## Recent Company News
- 2026-07-09 15:18 EST — [Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference - Wave Life Sciences](https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-2026-rbc-capital-markets-global-healthcare-conf-7c9ed053) — Source: Wave Life Sciences
- 2026-07-09 15:18 EST — [Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing - Wave Life Sciences](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-positive-update-on-restoraation-2-trial-wve-006-gal-28816cd9) — Source: Wave Life Sciences
- 2026-07-09 15:18 EST — [Wave Life Sciences to Present at Upcoming Investor Conferences - Wave Life Sciences](https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-wave-life-science-1abd2202) — Source: Wave Life Sciences
- 2026-07-09 15:18 EST — [Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases - Wave Life Sciences](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-initiation-of-phase-2a-portion-of-inlight-trial-of--01c48945) — Source: Wave Life Sciences
- 2026-07-09 15:18 EST — [Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation - Wave Life Sciences](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-july-14-2026--089ce376) — Source: Wave Life Sciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)